Building On 100 Years In India: The Next Big Things On GSK’s Horizon

GSK’s India chief talks to Scrip about new category creation in adult immunization with Shingrix seeing strong uptake, Nucala and Trelegy’s trajectory and oncology assets set for debut as the company steps into its 100th year of operation in the country. GSK expects to continue to transform its operating model as things evolve, he indicates in the concluding part of this interview.

GSK expects to shape the adult vaccination ecosystem in India

When GSK (then Glaxo Laboratories) introduced the infant formula milk brand Farex in India way back in 1924, it was the nutritional needs of infants that drove the decision. The baby food brand, which has long since changed hands, went on to become a household name in the country.

Hundred years down the line, GSK hopes to make a material impact at the other end of the spectrum – healthy aging

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

16 May 2025

• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

16 May 2025

• By Mandy Jackson

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.